Sort
21,453 grants matching “tuberculosis”
Phenotype MicroArray Analysis of Fastidious Pathogens
$923,041Barry Ronald Bochner · Biolog, Inc. · R42 · FY2009 · GM
Tuberculosis Control & Elimination
$922,952Glenn Wasserman · Hawaii State Department Of Health · U52 · FY2015 · PS
ULTIMATE
$922,713Reinout Van Crevel · Stichting Radboud Universitair Medisch Centrum I.O. · R01 · FY2021 · AI
Tuberculosis Second Line Drug Susceptibility Chip
$920,643Eric R Houpt · University Of Virginia · R01 · FY2011 · AI
Biology of lipoamide dehydrogenase and 2-hydroxy-3-oxoadipate synthase in Mtb
$920,600Carl F Nathan · Weill Medical Coll Of Cornell Univ · R01 · FY2014 · AI
Biology of lipoamide dehydrogenase and 2-hydroxy-3-oxoadipate synthase in Mtb
$920,600Carl F Nathan · Weill Medical Coll Of Cornell Univ · R01 · FY2015 · AI
Genes/Pathways for ATG Gene-dependent Inhibition of Viruses & Parasite Infection
$920,338Herbert W Virgin · Washington University · U19 · FY2016 · AI
Core 2: BSL-3 Practices Core
$920,265Scott Alderman · Duke University · UC7 · FY2023 · AI
(CIRCADIAN) Circadian Disruption as Mediator of Cardiometabolic Risk in Air Pollution
$920,087Sanjay Rajagopalan · Case Western Reserve University · R35 · FY2025 · ES
Biology of lipoamide dehydrogenase and 2-hydroxy-3-oxoadipate synthase in Mtb
$919,954Carl F Nathan · Weill Medical Coll Of Cornell Univ · R01 · FY2012 · AI
Biocontainment Research support services core
$919,306Farhang Alem · George Mason University · UC7 · FY2024 · AI
A Neonatal Monkey Model of Tuberculosis Vaccination
$919,284Chinnaswamy Jagannath · Methodist Hospital Research Institute · R01 · FY2019 · AI
GHESKIO HIV Clinical Trial Unit
$919,160Jean William Pape · Gheskio Center · UM1 · FY2015 · AI
Large Scale T Cell Epitope Discovery: Proteome-wide characterization of T cell epitopes from Mycobacterium tuberculosis in vaccination and active infection
$918,786Bjoern Peters · La Jolla Institute For Immunology · N01 · FY2021 · AI
KARABELO Clinical Trials Unit for NIAID Networks
$918,589Glenda E Gray · Wits Health Consortium (Pty), Ltd · UM1 · FY2016 · AI
ULTIMATE
$918,329Reinout Van Crevel · Stichting Radboud Universiteit · R01 · FY2020 · AI
Odorprint Based Disease Diagnostics
$918,295Dmitry Rinberg · New York University School Of Medicine · R01 · FY2024 · DC
TUBERCULOSIS ELIMINATION AND LABORATORY PROGRAM FUNDING
$918,184Barry Dickman · Philadelphia Departmentof Public Health · U52 · FY2010 · PS
India International Center for Excellence in Research
$917,866Thomas Nutman · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
TUBERCULOSIS ELIMINATION AND LABORATORY
$917,698Barry Dickman · Philadelphia Departmentof Public Health · U52 · FY2009 · PS
The Cloning Protein Production, Crystallization, and X-ray Data Collection Core
$916,735James C Sacchettini · Texas A&M Agrilife Research · P01 · FY2009 · AI
Immunotherapeutics and vaccines against anthrax, plague and tularemia
$916,440Zheng W Chen · University Of Illinois At Chicago · U01 · FY2008 · AI
Safety and Tolerability of Ultra-short Course Rifapentine and Isoniazid (1HP) for Prevention of Tuberculosis in HIV-Uninfected Individuals
$916,330Richard E Chaisson · Johns Hopkins University · U01 · FY2020 · AI
TUBERCULOSIS ELIMINATION AND LABORATORY
$916,326Chiyome L Fukino · Hawaii State Department Of Health · U52 · FY2006 · PS
Flow Direct: Next Generation Urine LFA for TB Diagnosis in Point-of-Care Settings
$916,195Jay Wyatt Warrick · Salus Discovery, Llc · R44 · FY2025 · AI